High-cost specialty drugs as a cost driver have increased the need for cost containment strategies that ensure access but reduce overutilization. The problem is that the market allows pharmaceutical companies to, legally, charge whatever they want.
Margaret E. O’Kane, MHA, referenced the 5000% overnight price hike by Turing Pharmaceuticals for Daraprim, a story that broke the day this panel discussion was filmed in September 2015. While it’s a legal move, it shows companies can essentially charge whatever the market can bear.
“They can charge, right now, more or less whatever they want, and then large payers, like Medicaid, and maybe large health insurers, like the VA, and so forth, can negotiate discounts,” Austin Frakt, PhD, explained. “And that’s just how it plays out. But those prices are going up and up and up, particularly in cancer care.”
He cited a suggestion from Peter Bach, MD, MAPP, of Memorial Sloan Kettering Cancer Center, that instead of paying for a drug, thinking about it as paying for what that drug does for specific diseases. So we would pay for the returns that drug delivers in a certain condition instead of the same price across the board.
This system is similar to what many European countries already do with reference pricing, where they group drugs into therapeutic classes that have similar effect and tag a price for all drugs in that class. The model is a different type of reference pricing than seen in the US, specifically in CalPERS.
However, he acknowledges that while pushing the price lower and lower to address the larger budget impact, we still need to be mindful of encouraging highly cost-effective therapies.
“It’s still possible, though, to have a drug that’s reasonably priced from a cost-effective point of view, but is so widely applicable that the total budget impact is huge,” Dr Frakt said.
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture (USDA) will begin testing ground beef for bird flu particles; rural Americans are more likely to die early from 1 of the 5 leading causes of death than those who live in urban areas.
Read More
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More